<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04934163</url>
  </required_header>
  <id_info>
    <org_study_id>202103054RINB</org_study_id>
    <nct_id>NCT04934163</nct_id>
  </id_info>
  <brief_title>Flow Rates of High-flow Nasal Cannula and Extubation Outcome</brief_title>
  <official_title>Effect of Flow Rates of Postextubation High-flow Nasal Cannula on Extubation Outcome: An Open-label, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, open-label, randomized controlled trial to evaluate the effect of&#xD;
      high-flow nasal cannula with a flow rate of 60 L/min versus 40 L/min after planned&#xD;
      extubationon on a composite outcome of reintubation and use of NIV.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, open-label, randomized controlled trial to evaluate the effect of&#xD;
      high-flow nasal cannula with a flow rate of 60 L/min versus 40 L/min after planned&#xD;
      extubationon on a composite outcome of reintubation and use of NIV in patients who are&#xD;
      intubated for hypoxemic respiratory failure.&#xD;
&#xD;
      [Study Procedures] Set flow rates of HFNC The flow rates of HFNC(high-flow nasal cannula) are&#xD;
      set as 40 L/min and 60 L/min, respectively in the two trial groups. Initial FiO2 setting is&#xD;
      100%, which would be titrated down to the minimal level to keep SO2 ≥ 92% within 30 minutes&#xD;
      after extubation. After that, the flow rate setting is fixed for 24hrs +/- 6 hrs in the two&#xD;
      groups. After that, the flow rate setting in both groups would be tapered to 30 L/min and&#xD;
      would be kept for 12 hours. Then, HFNC would be changed to conventional oxygen therapy to&#xD;
      keep SpO2≥ 92%.&#xD;
&#xD;
      [Outcome Measures] To increase the statistical power of this pilot trial, we used a composite&#xD;
      outcome of NIV use and or reintubation in 48 hours for the primary endpoint. Secondary&#xD;
      endpoints include mortality of different time points, physiological parameters(respiratory&#xD;
      rate, heart rate), ventilation/oxygenation data(PaO2/FiO2 ratio, pH) and patient comfort.&#xD;
      Exploratory endpoints include comparison between different flow rate settings.&#xD;
&#xD;
      [Primary endpoint] We hypothesized that higher flow setting of HFNC can reduce work of&#xD;
      breathing and can increase washout of dead space, which could result in lower re-intubation&#xD;
      rate and lower NIV use rate after planned extubation in hypoxemic patients. The primary&#xD;
      endpoint is a composite outcome of NIV use or reintubation in 48 hours between two groups of&#xD;
      different flow rates.&#xD;
&#xD;
      [Secondary endpoints] ICU mortality In-hospital mortality 28-day mortality Time to successful&#xD;
      liberation from mechanical ventilation AUC(area under curve) of respiratory rate (0-24 hours)&#xD;
      AUC of heart rate (0-24 hours) PaO2/FiO2 ratio at 4 and 24 hours Change of arterial CO2&#xD;
      level(mmHg) at 4 and 24 hours Proportion of respiratory acidosis (arterial blood gas:&#xD;
      pH&lt;7.35) at 4 and 24 hours Proportion of Intolerance at 4 and 24 hours Patient comfort&#xD;
      (measured by Visual Analog Scale) at 24 hours&#xD;
&#xD;
      [Sample size] The event rate of primary endpoint, defined as a composite outcome of NIV use&#xD;
      and or reintubation in 48 hours, was assumed to be 40% in the 40 L/min arms and 25% in the 60&#xD;
      L/min. We estimated that with a sample of 165 patients, the study would have 80% power to&#xD;
      detect a 15% absolute reduction in proportion of composite outcomes, at a two-sided type I&#xD;
      error rate of 5%.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A composite outcome of NIV(non-invasive ventilation) use or reintubation in 48 hours</measure>
    <time_frame>48 hours after extubation</time_frame>
    <description>Proportion of patients require NIV(non-invasive ventilation) support or reintubation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICU mortality</measure>
    <time_frame>ICU stay</time_frame>
    <description>Proportion of death in the ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-hospital mortality</measure>
    <time_frame>Hospital stay</time_frame>
    <description>Proportion of death in the hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28-day mortality</measure>
    <time_frame>28 days</time_frame>
    <description>Proportion of death in 28 days after extubation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to successful liberation from mechanical ventilation</measure>
    <time_frame>28 days</time_frame>
    <description>Definition of successful liberation from mechanical ventilation: not requiring mechanical ventilation support for &gt; 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(area under curve) of respiratory rate (0-24 hours)</measure>
    <time_frame>24 hours</time_frame>
    <description>measure respiratory rate every 2 hours during HFNC use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of heart rate (0-24 hours)</measure>
    <time_frame>24 hours</time_frame>
    <description>measure heart rate every 2 hours during HFNC use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PaO2/FiO2 ratio at 4 and 24 hours</measure>
    <time_frame>24 hours</time_frame>
    <description>PaO2: from arterial blood gas; FiO2:from HFNC setting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of arterial CO2 level(mmHg) at 4 and 24 hours</measure>
    <time_frame>24 hours</time_frame>
    <description>CO2 level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of respiratory acidosis (arterial blood gas: pH&lt;7.35) at 4 and 24 hours</measure>
    <time_frame>24 hours</time_frame>
    <description>Respiratory acidosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Intolerance at 4 and 24 hours</measure>
    <time_frame>24 hours</time_frame>
    <description>subjective intolerance (Eg. temperature setting, flow setting, interface....)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient comfort score at 24 hour</measure>
    <time_frame>24 hours</time_frame>
    <description>7-point scale which 7 indicates most comfortable and 1 indicates least comfortable</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Hypoxemic Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>60 L/min arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The flow rate of HFNC(high-flow nasal cannula) is set as 60 L/min after extubation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>40 L/min arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The flow rate of HFNC(high-flow nasal cannula) is set as 40 L/min after extubation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Flow rate setting of high-flow nasal cannula (initially 60L/min)</intervention_name>
    <description>The flow rates of HFNC(high-flow nasal cannula) is set as 60L/min(temperature:34°C).&#xD;
Initial FiO2 is 100%, which would be titrated down to the minimal level to keep SpO2 ≥ 92% within 30 minutes after extubation.&#xD;
After that, the flow rate setting is fixed for 24hrs +/- 6 hrs; then, is tapered to 30 L/min and kept for 12 more hours. Afterwards, HFNC would be changed to conventional oxygen therapy to keep SpO2≥ 92%.</description>
    <arm_group_label>60 L/min arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Flow rate setting of high-flow nasal cannula (initially 40L/min)</intervention_name>
    <description>The flow rates of HFNC(high-flow nasal cannula) is set as 40L/min(temperature:34°C).&#xD;
Initial FiO2 is 100%, which would be titrated down to the minimal level to keep SpO2 ≥ 92% within 30 minutes after extubation.&#xD;
After that, the flow rate setting is fixed for 24hrs +/- 6 hrs; then, is tapered to 30 L/min and kept for 12 more hours. Afterwards, HFNC would be changed to conventional oxygen therapy to keep SpO2≥ 92%.</description>
    <arm_group_label>40 L/min arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  invasive mechanical ventilation &gt; 48 hours&#xD;
&#xD;
          -  acute hypoxemic respiratory failure(PaO2/FiO2 &lt; 300 mmHg) as a main cause of invasive&#xD;
             mechanical ventilation.&#xD;
&#xD;
          -  planned extubation &amp; already passed a spontaneous breathing trial (SBT)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &lt; 20 years of ages&#xD;
&#xD;
          -  refusal to re-intubation&#xD;
&#xD;
          -  with terminal cancer&#xD;
&#xD;
          -  pregnant women&#xD;
&#xD;
          -  with a tracheal stoma or tracheostomy tube in situ&#xD;
&#xD;
          -  not feasible for high-flow nasal cannula(decided by the primary care team)&#xD;
&#xD;
          -  must required to use non-invasive ventilation immediately after extubation (decided by&#xD;
             the primary care team)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Fu-Chang Tsai, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Research Ethics Committee of the National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sheng-Yuan Ruan, MD</last_name>
    <phone>886-2-23123456</phone>
    <email>syruan@ntu.edu.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheng-Yuan Ruan, MD</last_name>
      <email>syruan@ntu.edu.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <results_reference>
    <citation>Ruan SY, Teng NC, Wu HD, Tsai SL, Wang CY, Wu CP, Yu CJ, Chen L. Durability of Weaning Success for Liberation from Invasive Mechanical Ventilation: An Analysis of a Nationwide Database. Am J Respir Crit Care Med. 2017 Sep 15;196(6):792-795. doi: 10.1164/rccm.201610-2153LE.</citation>
    <PMID>28170290</PMID>
  </results_reference>
  <results_reference>
    <citation>Saiphoklang N, Auttajaroon J. Incidence and outcome of weaning from mechanical ventilation in medical wards at Thammasat University Hospital. PLoS One. 2018 Oct 4;13(10):e0205106. doi: 10.1371/journal.pone.0205106. eCollection 2018.</citation>
    <PMID>30286153</PMID>
  </results_reference>
  <results_reference>
    <citation>Rochwerg B, Einav S, Chaudhuri D, Mancebo J, Mauri T, Helviz Y, Goligher EC, Jaber S, Ricard JD, Rittayamai N, Roca O, Antonelli M, Maggiore SM, Demoule A, Hodgson CL, Mercat A, Wilcox ME, Granton D, Wang D, Azoulay E, Ouanes-Besbes L, Cinnella G, Rauseo M, Carvalho C, Dessap-Mekontso A, Fraser J, Frat JP, Gomersall C, Grasselli G, Hernandez G, Jog S, Pesenti A, Riviello ED, Slutsky AS, Stapleton RD, Talmor D, Thille AW, Brochard L, Burns KEA. The role for high flow nasal cannula as a respiratory support strategy in adults: a clinical practice guideline. Intensive Care Med. 2020 Dec;46(12):2226-2237. doi: 10.1007/s00134-020-06312-y. Epub 2020 Nov 17.</citation>
    <PMID>33201321</PMID>
  </results_reference>
  <results_reference>
    <citation>Rochwerg B, Granton D, Wang DX, Helviz Y, Einav S, Frat JP, Mekontso-Dessap A, Schreiber A, Azoulay E, Mercat A, Demoule A, Lemiale V, Pesenti A, Riviello ED, Mauri T, Mancebo J, Brochard L, Burns K. High flow nasal cannula compared with conventional oxygen therapy for acute hypoxemic respiratory failure: a systematic review and meta-analysis. Intensive Care Med. 2019 May;45(5):563-572. doi: 10.1007/s00134-019-05590-5. Epub 2019 Mar 19.</citation>
    <PMID>30888444</PMID>
  </results_reference>
  <results_reference>
    <citation>Mauri T, Turrini C, Eronia N, Grasselli G, Volta CA, Bellani G, Pesenti A. Physiologic Effects of High-Flow Nasal Cannula in Acute Hypoxemic Respiratory Failure. Am J Respir Crit Care Med. 2017 May 1;195(9):1207-1215. doi: 10.1164/rccm.201605-0916OC.</citation>
    <PMID>27997805</PMID>
  </results_reference>
  <results_reference>
    <citation>Mauri T, Alban L, Turrini C, Cambiaghi B, Carlesso E, Taccone P, Bottino N, Lissoni A, Spadaro S, Volta CA, Gattinoni L, Pesenti A, Grasselli G. Optimum support by high-flow nasal cannula in acute hypoxemic respiratory failure: effects of increasing flow rates. Intensive Care Med. 2017 Oct;43(10):1453-1463. doi: 10.1007/s00134-017-4890-1. Epub 2017 Jul 31.</citation>
    <PMID>28762180</PMID>
  </results_reference>
  <results_reference>
    <citation>Mauri T, Galazzi A, Binda F, Masciopinto L, Corcione N, Carlesso E, Lazzeri M, Spinelli E, Tubiolo D, Volta CA, Adamini I, Pesenti A, Grasselli G. Impact of flow and temperature on patient comfort during respiratory support by high-flow nasal cannula. Crit Care. 2018 May 9;22(1):120. doi: 10.1186/s13054-018-2039-4.</citation>
    <PMID>29743098</PMID>
  </results_reference>
  <results_reference>
    <citation>Maggiore SM, Idone FA, Vaschetto R, Festa R, Cataldo A, Antonicelli F, Montini L, De Gaetano A, Navalesi P, Antonelli M. Nasal high-flow versus Venturi mask oxygen therapy after extubation. Effects on oxygenation, comfort, and clinical outcome. Am J Respir Crit Care Med. 2014 Aug 1;190(3):282-8. doi: 10.1164/rccm.201402-0364OC.</citation>
    <PMID>25003980</PMID>
  </results_reference>
  <results_reference>
    <citation>Rittayamai N, Tscheikuna J, Rujiwit P. High-flow nasal cannula versus conventional oxygen therapy after endotracheal extubation: a randomized crossover physiologic study. Respir Care. 2014 Apr;59(4):485-90. doi: 10.4187/respcare.02397. Epub 2013 Sep 17.</citation>
    <PMID>24046462</PMID>
  </results_reference>
  <results_reference>
    <citation>Hernández G, Vaquero C, González P, Subira C, Frutos-Vivar F, Rialp G, Laborda C, Colinas L, Cuena R, Fernández R. Effect of Postextubation High-Flow Nasal Cannula vs Conventional Oxygen Therapy on Reintubation in Low-Risk Patients: A Randomized Clinical Trial. JAMA. 2016 Apr 5;315(13):1354-61. doi: 10.1001/jama.2016.2711.</citation>
    <PMID>26975498</PMID>
  </results_reference>
  <results_reference>
    <citation>Hernández G, Vaquero C, Colinas L, Cuena R, González P, Canabal A, Sanchez S, Rodriguez ML, Villasclaras A, Fernández R. Effect of Postextubation High-Flow Nasal Cannula vs Noninvasive Ventilation on Reintubation and Postextubation Respiratory Failure in High-Risk Patients: A Randomized Clinical Trial. JAMA. 2016 Oct 18;316(15):1565-1574. doi: 10.1001/jama.2016.14194. Erratum in: JAMA. 2016 Nov 15;316(19):2047-2048. Erratum in: JAMA. 2017 Feb 28;317(8):858.</citation>
    <PMID>27706464</PMID>
  </results_reference>
  <results_reference>
    <citation>Fernandez R, Subira C, Frutos-Vivar F, Rialp G, Laborda C, Masclans JR, Lesmes A, Panadero L, Hernandez G. High-flow nasal cannula to prevent postextubation respiratory failure in high-risk non-hypercapnic patients: a randomized multicenter trial. Ann Intensive Care. 2017 Dec;7(1):47. doi: 10.1186/s13613-017-0270-9. Epub 2017 May 2.</citation>
    <PMID>28466461</PMID>
  </results_reference>
  <results_reference>
    <citation>Song HZ, Gu JX, Xiu HQ, Cui W, Zhang GS. The value of high-flow nasal cannula oxygen therapy after extubation in patients with acute respiratory failure. Clinics (Sao Paulo). 2017 Oct;72(9):562-567. doi: 10.6061/clinics/2017(09)07.</citation>
    <PMID>29069260</PMID>
  </results_reference>
  <results_reference>
    <citation>Theerawit P, Natpobsuk N, Petnak T, Sutherasan Y. The efficacy of the WhisperFlow CPAP system versus high flow nasal cannula in patients at risk for postextubation failure: A Randomized controlled trial. J Crit Care. 2021 Jun;63:117-123. doi: 10.1016/j.jcrc.2020.09.031. Epub 2020 Sep 28.</citation>
    <PMID>33012589</PMID>
  </results_reference>
  <results_reference>
    <citation>Jing G, Li J, Hao D, Wang T, Sun Y, Tian H, Fu Z, Zhang Y, Wang X. Comparison of high flow nasal cannula with noninvasive ventilation in chronic obstructive pulmonary disease patients with hypercapnia in preventing postextubation respiratory failure: A pilot randomized controlled trial. Res Nurs Health. 2019 Jun;42(3):217-225. doi: 10.1002/nur.21942. Epub 2019 Mar 18.</citation>
    <PMID>30887549</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 14, 2021</study_first_submitted>
  <study_first_submitted_qc>June 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2021</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>high-flow nasal cannula</keyword>
  <keyword>hypoxemic respiratory failure</keyword>
  <keyword>oxygen therapy</keyword>
  <keyword>postextubation respiratory failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

